The Weekly Checkup: Week of May 18-22, 2026

Issue #7 | Week of May 18-22, 2026

42 announced transactions this week, down from last week's 49, and lighter than the weekly average we've been running. Services 26, Technology 16, and 2 platform deals, with the platform count reflecting a genuinely quiet week for announcements. With the holiday Monday, next week is likely to be fairly light for deal announcements as well. On to the highlights:

Quorum Health announced an agreement to convert from a for-profit, PE-backed hospital system to a nonprofit, a move framed in the press release as a mission-driven evolution, but out goal is to provide our honest assessment of the situation, and out honest assessment is that it’s the last viable exit for a distressed rural operator carrying a Moody's Ca credit rating.

Medtronic announced a $650 million acquisition of SPR Therapeutics, a peripheral nerve stimulation company with FDA clearance in chronic pain. Boston Scientific made a $1.5 billion bet on MiRus's TAVR platform through a minority stake with an exclusive option to acquire, a structure worth unpacking on its own terms. And Eli Lilly acquired Engage Biologics for up to $202 million, proving it’s truly a weekly tradition.

Alpha Aesthetics Partners acquired Preva Aesthetics across two states in the same announcement, and Ballantyne Plastic Surgery changed hands in Charlotte. Three aesthetics transactions in a single week is more than noise, and it gives us an opportunity to do something I've been meaning to do: a proper market overview of the medical aesthetics and medspa category, including where it is in its consolidation arc, why the economics are different from other healthcare services categories, and what the current comp set actually looks like for buyers and sellers.

Quorum Health announced a definitive agreement with QKA Health Corporation (doing business as Healthside Partners) to transition from a for-profit, PE-backed hospital system to a nonprofit. The 11-hospital system operates across nine states, with approximately 75% of its hospitals serving as sole community providers or critical access hospitals. The transaction is expected to close in fall 2026 pending regulatory review.

My take: The press release language is mission-driven. The context is distressed. Quorum was spun off from Community Health Systems in 2016 with approximately 38 hospitals, filed for Chapter 11 bankruptcy in 2020 with $500 million in debt to restructure, and has spent the years since shrinking its portfolio and trying to find stable footing in one of the most economically challenging segments in healthcare: rural and mid-sized community hospitals with high Medicaid and Medicare dependence.

As of March 31, 2025, trailing twelve month revenue was reportedly $974 million, down from $1.7 billion in 2019, it’s last full year as a public company, and leverage was~12x EBITDA. Moody's currently rates Quorum Ca, the second-lowest rating on their scale, reserved for obligations in or near default. As a result, the $11 million 340b pharmacy savings and $13 million in estimated annual tax savings from nonprofit conversion are key to survival for an organization like Quorum.

The conversion structure is worth understanding because it does not produce a traditional purchase price. Rather than a buyer paying a stated sum, Quorum's equity holders (primarily Goldentree Asset Management) are accepting a reorganization into nonprofit status in exchange for whatever economic value the transaction preserves. The result is that there is no EV/revenue or EV/EBITDA multiple to report. For this newsletter's purposes, the Quorum conversion is a de facto distressed exit from rural hospital ownership, and it joins a pattern we can document: for-profit rural hospitals that have been unable to generate sufficient operating cash flow to service their capital structures are increasingly converting, merging with nonprofits, or closing. The Scope database includes several direct precedents for Quorum's own prior divestitures, all of which illustrate the same dynamic. In 2022, Deaconess Health System acquired four Illinois Quorum hospitals for $146 million at 0.69x revenue and 4.7x EBITDA on financial statements that actually showed a modest profit. In 2023, Quorum sold Vista Medical Center East for $23.5 million, a 0.16x revenue multiple on a hospital operating well below breakeven. In 2020, Henderson County Community Hospital, a Quorum facility, was sold for $1 million, effectively for free.

Here’s the dichotomy I want to highlight explicitly: the for-profit hospital divestiture market has been active over the last two years, with motivated sellers (primarily CHS and Tenet) finding very willing buyers (nonprofit health systems with capital and strategic rationale to consolidate). Many of those transactions have cleared at surprisingly robust multiples when the target hospital has a defensible market position and a path to increased profitability under new ownership. But that market is not operating uniformly across all hospital types. The facilities that can command hefty multiples are the ones buyers want: hospitals in markets with favorable payer mix, operational improvement potential, and strategic fit with an acquirer's existing footprint. The facilities being converted to nonprofit, closed, or sold for nominal consideration are the ones nobody wants at any conventional multiple, because the economics do not work in the current Medicaid rate environment. Often these organizations are facing significant financial struggles prior to factoring in the One Big Beautiful Bill Act's $1 trillion in projected Medicaid cuts over ten years. Rural hospitals where Medicaid covers 40-60% of patient revenue and operating margins are already negative are facing a funding environment that makes Quorum's path look less like an outlier and more like a preview… and the $50 billion rural hospital relief fund in the legislation is structured to cover roughly $4.5 million per rural hospital per year over five years, which is mathematically insufficient for most of the hospitals it is meant to protect.

The key take away for buyers, sellers, and advisors: the for-profit hospital divestiture market has two distinct sub-markets right now. The first includes hospitals with genuine strategic value to a motivated nonprofit or health system acquirer, and those transactions are happening at multiples that look high relative the historical market for general acute care hospitals. The second includes hospitals without a viable buyer at any market multiple, and those situations are increasingly resolved through nonprofit conversions, closures, or transfers that involve no economic consideration. Knowing which type you are dealing with determines whether you should be underwriting a valuation or identifying off-ramps.

Medtronic announced its intent to acquire SPR Therapeutics, a developer of temporary percutaneous peripheral nerve stimulation (PNS) technology for chronic pain, for $650 million upfront. SPR's SPRINT PNS System is FDA-cleared for multiple chronic pain indications, including knee, shoulder, and back pain.

My take: The $650 million upfront figure is the headline, but the technology distinction is the analytical point. PNS is a temporary, percutaneous technology: patients wear the device for a defined treatment period (typically 60 days), then remove it, with the expectation that the therapeutic effect persists. That is a materially different economic and regulatory profile than implantable spinal cord stimulation (SCS), which is Medtronic's dominant chronic pain franchise. The SPRINT system is competing at the less invasive end of a pain market that also includes SCS, radiofrequency ablation, and an expanding pharmacologic toolkit including GLP-1 adjacents. What makes SPR strategically interesting to Medtronic is not that it replaces SCS but that it addresses patients who are not SCS candidates and procedures that can be performed in an office or outpatient setting rather than an OR. The channel implications are meaningful: a $650 million bet on outpatient, temporary PNS suggests Medtronic believes the pain management access point is shifting away from implant-centered care. For anyone advising or valuing pain management physician practices, the structural shift toward outpatient-delivered neuromodulation is worth tracking.

Boston Scientific announced a $1.5 billion investment for a 34% equity stake in MiRus, a company developing a balloon-expandable transcatheter aortic valve replacement system. The agreement gives BSX an exclusive option to acquire the full TAVR business for an additional $3 billion in payments, with a separate option on MiRus's mitral and tricuspid replacement valve assets.

My take: The structure deserves more attention than the headline number. This is not a conventional acquisition. BSX is paying $1.5 billion for a minority position and an option, not a company. The implied enterprise value at the 34% stake price ($1.5B / 0.34 = approximately $4.4 billion) is being paid for a TAVR platform that has not yet received US FDA approval and has not commercially launched in the US. The strategic context explains why: Boston Scientific has now made three attempts to establish a TAVR position. The Acurate Neo2 was pulled from development in 2025 after failing to match competitor outcomes in a head-to-head trial. The option structure here lets BSX access the technology and share in its development without owning the full risk of a technology that is not yet in the market. The Medtronic/Contego precedent is the closest structural comparable I could find: Medtronic was a minority investor in Contego for several years before announcing an increased investment plus a formal option to acquire alongside a distribution deal in January 2025. The BSX/MiRus option also includes a milestone-based payment structure, meaning the $3 billion in additional payments for full acquisition are contingent on clinical and regulatory outcomes rather than payable upfront. If the TAVR pivotal trial produces strong data and FDA clearance follows, the option looks cheap at $3 billion. If it doesn't, BSX has paid $1.5 billion for a minority position in a technology that may not reach its commercial potential, and they have been here before.

I tracked 39 additional transactions this week, including aesthetics consolidation (Dominion Aesthetic / BellaMia Technologies at $200 million for the combined robotic body contouring and laser platform), home care technology (Dina Care / Integrated Home Care Services), pediatric home health (Circle of Care / Therapy 2000), and the formation of the world's largest dedicated healthcare investment manager (GHO Capital / CBC Group at $21 billion in combined AUM).

This week we’re doing a category deep-dive rather than a single deal, modeled on how we covered dentistry in Issue #4. Three aesthetics transactions in this week's volume, steady platform formation activity from well-capitalized sponsors, and an active listing set that spans from the smallest to largest single location medspas makes this the right moment to lay out what we know about how medspas and aesthetic medicine practices trade.

Medical aesthetics is a large and genuinely unusual healthcare category. It sits at the intersection of healthcare services and consumer discretionary: the procedures are clinically administered (injectables, laser treatments, body contouring, chemical peels, skin tightening, radiofrequency, and an expanding GLP-1-adjacent weight loss component) but are paid almost entirely out of pocket by patients with zero switching cost and high price sensitivity. That cash-pay structure is both the category's primary appeal to investors and its primary vulnerability.

The appeal is obvious: no claims processing, no payer contract negotiations, no reimbursement rate risk. A medspa's revenue is a function of patient volume, procedure mix, and pricing power, all of which can be managed actively without any of the reimbursement variables that dominate most physician practice categories. EBITDA margins for well-run medspas typically range from 20% to 35%, which is well above primary care, behavioral health, and most physician specialists.

The vulnerability is less often discussed. Cash-pay patients are economically rational. They defer, trade down, or stop spending when household budgets tighten, when competitive supply enters their market, or when they find a cheaper or more convenient alternative. The American Med Spa Association reported that 2025 saw the first year-over-year revenue decline in the aesthetic space broadly, driven by supply-demand imbalance: the number of medspa locations grew from roughly 10,000 in 2024 to a projected 12,000-plus by 2026, while consumer demand growth slowed. Individual well-run practices with strong brand equity and repeat-visit economics have remained resilient, but the category-level dynamic is one of supply outrunning demand for the first time since the consolidation wave began in earnest.

The dental parallel from Issue #4 is useful as a reference, but the aesthetics category is meaningfully earlier in its roll-up cycle. PE-owned or PE-affiliated medspas represent approximately 3% to 4% of the roughly 10,000-plus locations in the US, according to the American Med Spa Association's 2024 State of the Industry Report. In dentistry, PE consolidation began in earnest in the mid-2000s and by 2024 had reached roughly 15% to 20% of locations under DSO ownership. Medical aesthetics in 2026 is where dentistry was around 2010 to 2012: active platform formation, a fragmented independent base that is larger than most investors realize, and multiples that are being set by competitive processes rather than established norms.

The active platforms as of this writing include Empower Aesthetics (Shore Capital), Alpha Aesthetics Partners (Thurston Group), Advanced MedAesthetic Partners (Leon Capital), Sono Bello, Well Labs+, Aviva Aesthetics, and MD Esthetics (New Harbor Capital), among more than 30 active PE platforms competing for quality independent practices. Several of these platforms are approaching the end of their initial hold period and are expected to recapitalize or seek exits in the next 12 to 18 months. When a recapitalization happens, the incoming sponsor typically needs to demonstrate growth to justify a premium on the prior entry multiple, which tends to accelerate add-on acquisition activity. The aesthetics consolidation wave may be early in aggregate terms, but within the platforms that are recapitalizing, the M&A activity will intensify.

The secondary market data shows a wide range that is best understood by size and sophistication tier rather than a single blended multiple:

Solo or small-group practices (revenue below $2 million) trade primarily on owner cash flow, and the multiples reflect the operational dependency on the selling physician or practitioner. Secondary market listings in this range typically show asking prices of 2x to 4x cash flow, with the multiple contracting sharply when the owner is the primary provider and the patient relationships are not demonstrably transferable. Our own study of current and recently removed medspa listings from last year showed a range of 0.6x to 1.25x revenue and 2.1x to 3.9x cash flow at the 25th and 75th percentiles, with medians of approximately 1x revenue and 2.9x cash flow. Those cash flow multiple have ticked up half a turn in the current batch of active listings.

Multi-location, operationally mature platforms (revenue above $3 million, with an employed clinical team rather than owner-as-provider) trade at materially higher multiples when sold to institutional buyers. PE platform acquisitions and strategic roll-up transactions have cleared in the 5x to 9x EBITDA range for quality assets with documented revenue growth, favorable demographics, and defensible payer relationships (membership programs, subscription models, employer wellness contracts). The gap between secondary market multiples and institutional buyer multiples is significant and is partly a function of deal preparation: a practice that has normalized its financials, documented its patient acquisition economics, and includes a continuing clinical team with correctly structured employment agreements will trade at a premium.

The corporate practice of medicine issue in aesthetics is more nuanced than in physician-heavy specialties like orthopedics or cardiology, but it is not absent. Most medspa services can be administered by nurse practitioners and physician assistants operating under physician supervision, and the physician supervision model varies meaningfully by state. Among major markets, Texas and California have stricter oversight requirements, while Florida is more permissive. Several states have specifically addressed the MSO structure for aesthetics practices in recent rule updates, and the direction is toward more scrutiny rather than less. Any non-physician buyer of a medspa with injectable or laser services needs a properly structured MSO and medical director arrangement, and the fair market value of that management fee is an area where buyers frequently underinvest in diligence. Improperly structured arrangements create both regulatory and tax exposure.

The Ballantyne Plastic Surgery and Alpha/Preva transactions from this week's volume are different from the typical medspa roll-up in an important way: plastic surgery is a physician-only specialty, and the corporate practice and ownership rules that apply to plastic surgery practices are closer to those governing orthopedic or neurosurgical practices than to those governing a cash-pay injectable medspa. A buyer acquiring a plastic surgery practice needs to understand that the billable surgical revenue is physician-generated and physician-dependent in a way that Botox injections are not. The valuation methodology for the surgical component and the injectable or cosmetic component of a combined practice should be separated, because they have different transferability profiles, different regulatory constraints, and different multiple ranges.

This week's listings are all in the medical aesthetics and medspa category, providing a cross-section of the market at different size tiers, states, and practice types.

Location: Massachusetts (undisclosed) | Asking Price: $5.0M | Revenue: $1.83M | Cash Flow: $900K | CF Margin: 49.2% | Price / Revenue: 2.73x | Price / Cash Flow: 5.56x

25-year-old plastic surgery practice with an AAA location, currently operating only a few days per week with no active marketing. Owner holds a third-party valuation supporting the asking price and is open to equity retention and extended transition. Described growth opportunities include injectable services, increased OR utilization, and expanded service offerings.

My take: The 49% cash flow margin and the "a few days per week, no marketing" description tell the same story: this is a highly profitable solo practice built on a 25-year referral base and patient relationships that belong, to an uncertain degree, to the selling surgeon. The 2.73x revenue multiple is above the range of what plastic surgery practices have been trading for as secondary market transactions, and it appears to be pricing in both the growth optionality the seller identifies and the minimal clinical work characterization. As always, transferability is a major question. Plastic surgery patient relationships, particularly for elective cosmetic procedures, are among the most physician-dependent in medicine: patients choose a specific surgeon by reputation, referral, and before-and-after results. The transition period with the selling physician is not optional; it is the primary value preservation mechanism. Massachusetts does not have a particularly aggressive CPOM doctrine for surgical practices, but any non-physician buyer will still need an MSO structure and a supervising physician arrangement for the non-surgical aesthetic components.

Location: Manhattan, NY | Asking Price: $2.8M | Revenue: $2.08M | Cash Flow: $832K | CF Margin: 40.0% | Price / Revenue: 1.35x | Price / Cash Flow: 3.37x

Upscale Manhattan medspa with 15% to 20% projected sales growth in 2025. Fully staffed and turnkey. Physician ownership required (PLLC compliant). Price recently reduced.

My take: The 3.37x cash flow multiple and the price reduction are interesting. The multiple is pretty cheap for a growing Manhattan medspa of this size with 40% margins: comparable assets with documented growth appear to have cleared closer to 4x to 5x cash flow. The price reduction suggests either that the broker's initial pricing was too aggressive, that the physician ownership requirement is limiting the buyer universe, or that diligence on prior offers revealed something that compressed the price. The "physician ownership required (PLLC compliant)" disclosure is important: New York's business corporation law restricts healthcare practice ownership to licensed professionals in the relevant specialty, and a non-physician buyer cannot simply own this practice directly. The MSO structure works in New York but adds complexity and legal cost that an institutional buyer must price. For a licensed aesthetic medicine physician or NP looking to acquire a going-concern Manhattan platform with a trained staff and existing patient base, this is worth a closer look at the revenue composition and growth driver before the price reduction opportunity closes.

Location: Atlanta, GA | Asking Price: $1.15M | Revenue: $2.21M | Cash Flow: $686K | CF Margin: 31.0% | Price / Revenue: 0.52x | Price / Cash Flow: 1.68x

Contemporary integrative medspa built around recurring memberships and multi-visit programs in the self-care and bio-optimization space. The listing targets growth-minded operators, language that tends to signal either genuine platform potential or a business that requires more active management than the current owner is providing.

My take: The 1.68x cash flow multiple on a $686,000 cash flow business in Atlanta is cheap enough to demand an explanation, and the most likely one is that "integrative med spa" is doing a lot of definitional work in the listing description. The bio-optimization framing, recurring membership model, and multi-visit programs suggest a service mix that probably includes IV therapy, hormone optimization, peptides, and possibly hyperbaric or red light components alongside more standard medspa offerings. That combination sits in a regulatory gray zone that varies meaningfully by state: Georgia's supervision requirements for some of these services are more permissive than California's or New York's, but the licensure picture for IV therapy and hormone prescribing still requires a physician or advanced practice provider in the clinical chain, and the transferability of that arrangement on a change of ownership is the first thing a buyer should verify. The membership model may be a genuine asset here, but needs diligence. Recurring membership revenue in an aesthetics or wellness context creates a baseline cash flow that a pure fee-for-service medspa does not have, reduces customer acquisition cost over time, and is the primary reason institutional buyers pay a premium for platforms with documented membership retention. The 0.52x revenue multiple suggests that the membership component has little value, which is either a pricing opportunity or a signal that the membership base is smaller or more churny than the description implies. Atlanta is a strong market for integrative and aesthetic wellness, with demographics and discretionary spending that support the model. A buyer with operational experience in membership-based wellness concepts will find the 1.68x entry point attractive if the membership metrics hold up in diligence. A buyer without that experience should be cautious: "growth-minded operators" in a listing description is frequently a seller's way of saying the buyer better roll up their sleeves to make this work.

Location: Anaheim, CA (Orange County) | Asking Price: $2.75M | Revenue: $1.57M | Cash Flow: $577K | CF Margin: 36.7% | Price / Revenue: 1.75x | Price / Cash Flow: 4.77x

Established in 2001 by founding physicians. Premier aesthetic destination in Southern California's Colony District of Anaheim. 25 years of operating history.

My take: The 25-year operating history in a single location is the asset here. In a market as competitive as Orange County, surviving for 25 years with consistent margins means either genuine brand equity, a loyal patient base that has survived multiple competitive entrants, or both. The primary diligence question is California-specific: California has among the most restrictive corporate practice of medicine rules in the country, and any transaction that results in non-physician ownership of clinical operations will need a carefully structured MSO arrangement. California's AB 1112 and related statutes mean that the management fee and clinical services agreement between the MSO and the professional corporation need to be explicitly structured and defensible under both state law and Stark/AKS principles. A buyer without California-specific healthcare counsel should not proceed to LOI without legal review. If the structure is clean, a 4.77x cash flow multiple on a 25-year-old Orange County practice with documented margins is probably reasonable, and there is genuine upside in a practice that has presumably grown organically without a marketing program.

Location: Bexar County, TX (San Antonio area) | Asking Price: $650K | Revenue: $1.70M | SDE: $277K | SDE Margin: 16.3% | Price / Revenue: 0.38x | Price / SDE: 2.34x

Well-established luxury spa in a high-income Bexar County residential corridor, offering facials, body services, and medical aesthetics. Current owner operates semi-absentee. Approximately 250 new clients per month. Founded 2020. Inventory $15K, FF&E $50K included.

My take: Three things stand out immediately, and none of them are the multiple. First, the 16.3% SDE margin on $1.7 million of revenue is low for a business described as a luxury medspa with medical aesthetics. Well-run medspas with a genuine aesthetic medicine component typically produce 25% to 35% margins; 16% suggests either that the revenue mix is weighted toward lower-margin spa and facial services rather than injectables and laser, that the cost structure has not been optimized, or that the SDE figure includes a market-rate management salary for the semi-absentee owner that has not been fully backed out. The distinction matters because a buyer who steps into an active operating role would see a different economic picture than a buyer who maintains the semi-absentee structure. Second, the founding date of 2020 means this business was built entirely in the post-COVID aesthetics boom, which raises a fair question about how its revenue and client base perform in a softer consumer environment. 250 new clients per month is a strong acquisition number, but new client acquisition is the expensive part of the medspa model; what matters more is retention rate and repeat visit frequency, neither of which is disclosed. Third, Texas's medical aesthetics supervision framework is worth flagging for any buyer: Texas has historically maintained stricter physician delegation rules for injectable and laser services than many other states, and the "medical aesthetics" component of this spa requires a supervising physician arrangement that needs to be verified, documented, and confirmed as transferable before closing. The 2.34x SDE ask is cheap on its face and becomes cheaper still if a buyer can rationalize the cost structure and grow the higher-margin injectable and laser mix. But the due diligence list here may be longer than the listing description suggests.

That's it for Issue #7.

See you next Tuesday.

Will Hamilton, CVA Founder, Scope Research and HealthFMV

The Weekly Checkup is published every Tuesday morning. Written for general informational purposes. Engagements through Scope Research or HealthFMV require a separate agreement.